Pharmaceutical Technology's 2005 Manufacturing Rankings - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's 2005 Manufacturing Rankings


Pharmaceutical Technology



Table I: The TOP 50, by Revenue
For its first snapshot of US pharmaceutical manufacturing activity, Pharmaceutical Technology reviewed five sources of information: our sister publication Pharmaceutical Executive's annual ranking of sales revenue and research and development (R&D) investment (see Table I); prescription (Rx) volumes (see Table II) tabulated by IMS Health (Fairfield, CT, http://www.imshealth.com/); the US Food and Drug Administration's database of approved drugs (see Tables III–V); company statements on manufacturing facility investments and rationalizations; and long-term capital investment plans tracked by Industrial Info Resources (Sugar Land, TX, http://www.industrialinfo.com/).

Product portfolios

Drugs@FDA is FDA's database of prescription and over-the-counter (OTC) human drugs currently approved for sale in the United States (1). The database does not include vaccines or OTC drugs that were not approved through a new drug application (NDA).


Table II: Top corporations by total US-dispensed prescriptions, 2005
Of the 21,502 products listed in Drugs@FDA (accessed on May 30, 2006), 12,708 are currently active. Of these, 93% (11,807) are approved for prescription use, 400 are listed for OTC sale, and the remaining 501 have "tentative approval."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here